• Price (EUR)98.61
  • Today's Change-4.03 / -3.93%
  • Shares traded97.00
  • 1 Year change+34.35%
  • Beta1.0182
Data delayed at least 15 minutes, as of Mar 04 2021 07:20 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.

  • Revenue in USD (TTM)5.53bn
  • Net income in USD810.00m
  • Incorporated1999
  • Employees16.40k
  • Location
    Agilent Technologies Inc5301 Stevens Creek BlvdSANTA CLARA 95051-7201United StatesUSA
  • Phone+1 (408) 345-8886
  • Fax+1 (408) 345-8474
  • Websitehttps://www.agilent.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
A:NYQ since
Resolution Bioscience IncAnnounced02 Mar 202102 Mar 2021Announced-7.62%695.00m
Data delayed at least 15 minutes, as of Mar 05 2021.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.